Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS

NCT04530838 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04530838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04530838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 16, 2020
Completion date
April 2, 2022
Enrollment
668 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal disease